Use the hyperlinks, where available to access additional clinical trial information.
A Phase 3, Randomized Study of Nivolumab Plus Ipilimumab in Combination With Chemotherapy vs Chemotherapy Alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer
Bristol-Myers Squibb (BMS)
In this trial, participants will be randomized into one of two modules. In Module A, participants will receive specified doses of immunotherapy (Ipilimumab and Nivolumab) and chemotherapy (Carboplatin, Paclitaxel, Pemetrexed and Cisplatin)on specified days. In Module B, participants will only receive specified doses of chemotherapy (Carboplatin, Paclitaxel, Pemetrexed and Cisplatin)on specified days.